Enzyme-sensitive radiolabeling reagent to reduce renal radioactivity after administration of radiolabeled peptide for cancer therapy

点击翻译按钮获取中文摘要

When radiolabeled carcinophilic peptides are administered for cancer therapy, high radioactivity is observed in the normal kidneys. I previously developed a radiolabeling reagent (HML) to reduce the renal radioactivity. The goal of this study is to develop the radiolabeling reagent which realizes not only reduction of the renal radioactivity but also elevation of radioactivity levels in the tumor. The new radiolabeling reagent showed low renal radioactivity levels compared with a conventi onal reagent although the renal radioactivity was higher than that for HML. Radioactivity levels in the tumor will be evaluated in the near future.